Skip to main content
AdvisorShares Psychedelics ETF—— (—)Compass Pathways—— (—)Definium Therapeutics—— (—)GH Research—— (—)Helus Pharma—— (—)MIRA Pharmaceuticals—— (—)Neuphoria Therapeutics—— (—)Eli Lilly—— (—)Johnson & Johnson—— (—)AbbVie—— (—)Otsuka Pharmaceutical—— (—)Numinus Wellness—— (—)Optimi Health—— (—)PharmAla Biotech—— (—)Enveric Biosciences—— (—)Incannex Healthcare—— (—)Aurora Cannabis—— (—)Cronos Group—— (—)SNDL—— (—)Bright Minds Biosciences—— (—)PharmaTher Holdings—— (—)IM Cannabis—— (—)MariMed—— (—)Vireo Growth—— (—)
Loading prices
Back to the NewsWire

Economist

Published November 18, 2026

The legalisation of psychedelic drugs offers potential—and pitfalls - The Economist

Read the full story at Economist

" Psychedelic medicines, including a synthetic form of psilocybin, are nearing regulatory approval in America, raising questions about.

Surfaced by 5 Google Alerts

  • Psychedelics
  • LSD
  • Psychedelics europe
  • Psychedelics south america
  • Psychedelic biotech